Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency.
We examined the pharmacokinetics of the new beta-lactam agent, cefoperazone, in normal and functionally anephric dialysis subjects with normal liver function. All subjects received 3 g of cefoperazone intravenously, and serial serum and urine samples were taken thereafter for up to 36 h. The serum levels, volume of distribution (0.22 liter/kg, normal; 0.19 liter/kg; dialysis), beta half-life (2.07 h, normal; 2.03 h, dialysis), and total body clearance (96.2 ml/min, normal; 92.9 ml/ min, dialysis) were all not significantly different between the two groups. Cefoperazone may be administered without adjustment of dose for any degree of renal dysfunction to patients with normal hepatic function.
D000328:Adult; D002438:Cefoperazone; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D002511:Cephalosporins; D002438:Cefoperazone